OBJECTIVES:  Immune-mediated rheumatic disease (IMRD) including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS), are severe and disabling chronic diseases in rheumatology. Bioogics such as subcutaneous tumor necrosis factor-alpha inhibitors (SC-TNFis) have transformed the management of the diseases. The study objective was to describe treatment persistence in a real-world setting, among patients diagnosed with IMRD, initiating treatment with golimumab (GLM) in France. METHODS:  The Système National d’Information Inter-régime [French national health insurance scheme information-sharing system] database lists all outpatient and inpatient healthcare consumption for individuals covered by the general health insurance scheme. Patients with RA, PsA or AS were included through Long Term Disease (LTD) status and hospital admission, based on ICD-10 codes. Then, patients were then identified through filled prescription of GLM between 06/01/2012 and 12/31/2013. A sensitivity analysis was conducted on patients with no subcutaneous or intravenous biotherapy before initiating GLM. Persistence was estimated using Kaplan Meier analysis at 12 and 24 months. RESULTS: A total of 1,315 patients initiating GLM with RA were identified, 2,656 with AS and 514 with PsA. For all IMRD patients (bionaïves or not) 12 months persistence rate was 54.7%. 12 month persistence rate was 56.6% for RA, 54.5% for AS and 50.8% for PsA. 24 month persistence rates were 40.1%, 41.0% and 35.0% for RA, AS and PsA, respectively. For all IMRD patients GLM persistence rates was 60.2% at 12 months and 47 % at 24 months. Persistence rate at 12 months was 63.8% in RA, 58.9% in AS and 55.9% in PsA; and 48.5% at 24 months in RA, and 44.1% in AS, and 57.1% in PsA. CONCLUSIONS:  GLM persistence rates at 12 months are between 55% (bionaïve and bioswitch patients) and 60% (bionaïve patients only). Those results confirm persistence rates published in the literature at 12 months for naïve patients.